The US Food and Drug Administration’s biologics center has one less “dangling” accelerated approval on the books now that GSK plc’s meningococcal B vaccine Bexsero has converted to regular approval.
GSK’s supplemental biologics license application cleared the agency on 19 August, using data from the confirmatory trial to revise the...







